Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.75 |
| ▸ | PDE1A | P54750 | 8/20 | 0.75 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.75 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.75 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.75 |
| ▸ | PDE6A | P16499 | 2/20 | 0.73 |
| ▸ | PDE2A | O00408 | 1/20 | 0.73 |
| ▸ | PDE6D | O43924 | 1/20 | 0.73 |
| ▸ | PDE9A | O76083 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | PDE6G | P18545 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | PDE6B | P35913 | 1/20 | 0.73 |
| ▸ | PDE6C | P51160 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.73 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655362 | 1.00 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL6340102 | 0.94 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL974554 | 0.94 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL6330112 | 0.93 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL6332643 | 0.93 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL6334314 | 0.93 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL8220166 | 0.92 | PDE5A (0.76) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL5931959 | 0.91 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL30594464 | 0.91 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL29663760 | 0.91 | PDE5A (0.77) | PDE5APDE1APDE1BPDE1CPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845328-B2 | Method for manufacturing of vardenafil and its salts | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2017-12-19 | — | — | US | claimed |
| WO-2023244059-A1 | METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-4259634-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| CN-116848116-A | Novel compounds as dual androgen receptor and phosphodiesterase inhibitors | 日东制药株式会社 | 2023-10-03 | — | — | CN | disclosed |
| US-20220380376-A1 | Nitrogen Oxide-Donating PDE-5 and/or PDE-6 Inhibitor Compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-12-01 | — | — | US | disclosed |
| EP-4058457-A2 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS | Ildong Pharmaceutical Co., Ltd. (KR) | 2022-09-21 | — | — | EP | disclosed |
| CN-115038704-A | Nitrogen oxide donating PDE-5 and/or PDE-6 inhibitor compounds | 日东制药股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20050070541-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040067945-A1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| EP-1368353-A1 | 2-ALKOXYPHENYL SUBSTITUTED IMIDAZOTRIAZINONES | Bayer Aktiengesellschaft (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-6566360-B1 | Administering 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position for therapy of hypertrophy of the prostate, incontinence or female sexual dysfunction in mammals | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| WO-2002064593-A1 | 2-ALKOXYPHENYL SUBSTITUTED IMIDAZOTRIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-22 | — | — | WO | disclosed |
| US-6362178-B1 | TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-26 | — | — | US | disclosed |
| EP-1049695-B1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2002-02-13 | — | — | EP | disclosed |
| EP-1174431-A2 | 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors | Bayer Aktiengesellschaft (DE) | 2002-01-23 | — | — | EP | disclosed |
| EP-1049695-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999024433-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380376-A1 | Nitrogen Oxide-Donating PDE-5 and/or PDE-6 Inhibitor Compounds | PDE6G, PRKG1, PRKG2 | PDE5A 4/4885PDE1A 27/4885PDE1B 28/4885 |
| US-20050070541-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | PDE5A 1/4885PDE1A 7/4885PDE1B 9/4885 |
| US-20040067945-A1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.